Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.007
Buy
RSI(14)
58.285
Neutral
STOCH(KDJ)(9,3,3)
58.111
Buy
ATR(14)
0.164
High Vlolatility
CCI(14)
98.354
Neutral
Williams %R
19.149
Overbought
TRIX(12,20)
0.445
Sell
StochRSI(14)
100.000
Buy
WHWK
WHWK2.500USD
-0.060-2.34%
Market hours （ET）Quotes delayed by 15 min
117.82MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of WHWK
Currency: USD Updated: 2025-12-19Key Insights
Whitehawk Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 87/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
WHWK's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Hold
Current Rating
2.000
Target Price
-16.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
WHWK Highlights
StrengthsRisks
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 70.76% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.98M.
Fairly Valued
The company’s latest PE is -4.06, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.33M shares, decreasing 13.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.34M shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Whitehawk Therapeutics Inc is 8.03, ranking 87/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 41.45%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.44
Operational Efficiency
10.00
Growth Potential
6.48
Shareholder Returns
7.23
WHWK's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Whitehawk Therapeutics Inc is 7.63, ranking 56/158 in the Pharmaceuticals industry. Its current P/E ratio is -4.06, which is -57.46% below the recent high of -1.73 and -809.66% above the recent low of -36.96.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 87/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Whitehawk Therapeutics Inc is 6.00, ranking 130/158 in the Pharmaceuticals industry. The average price target for Whitehawk Therapeutics Inc is 2.00, with a high of 2.00 and a low of 2.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
2.000
Target Price
-16.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
WHWK
3
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Whitehawk Therapeutics Inc is 8.42, ranking 64/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.81 and the support level at 2.14, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.408
Buy
MA10
2.441
Buy
MA20
2.363
Buy
MA50
2.288
Buy
MA100
2.064
Buy
MA200
1.940
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Whitehawk Therapeutics Inc is 5.00, ranking 74/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 68.61%, representing a quarter-over-quarter decrease of 14.55%. The largest institutional shareholder is The Vanguard, holding a total of 1.34M shares, representing 2.85% of shares outstanding, with 74.04% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Whitehawk Therapeutics Inc is 1.68, ranking 146/158 in the Pharmaceuticals industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.46
VaR
+6.58%
240-Day Maximum Drawdown
+61.13%
240-Day Volatility
+98.28%
Return
Best Daily Return
60 days
+24.29%
120 days
+24.29%
5 years
+63.16%
Worst Daily Return
60 days
-15.33%
120 days
-15.33%
5 years
-56.42%
Sharpe Ratio
60 days
+1.66
120 days
+1.19
5 years
-0.14
Risk Assessment
Maximum Drawdown
240 days
+61.13%
3 years
+89.41%
5 years
+96.85%
Return-to-Drawdown Ratio
240 days
-0.41
3 years
-0.30
5 years
-0.18
Skewness
240 days
+0.79
3 years
-0.50
5 years
+1.57
Volatility
Realised Volatility
240 days
+98.28%
5 years
+91.99%
Standardised True Range
240 days
+5.94%
5 years
+27.12%
Downside Risk-Adjusted Return
120 days
+198.88%
240 days
+198.88%
Maximum Daily Upside Volatility
60 days
+170.49%
Maximum Daily Downside Volatility
60 days
+74.14%
Liquidity
Average Turnover Rate
60 days
+0.26%
120 days
+0.35%
5 years
--
Turnover Deviation
20 days
-76.43%
60 days
-72.83%
120 days
-63.80%
Peer Comparison
Pharmaceuticals
WHWK
6.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of WHWK?
The TradingKey Stock Score provides a comprehensive assessment of WHWK based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of WHWK’s performance and outlook.
How do we generate the financial health score of WHWK?
To generate the financial health score of WHWK, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects WHWK's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of WHWK.
How do we generate the company valuation score of WHWK?
To generate the company valuation score of WHWK, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare WHWK’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of WHWK’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of WHWK.
How do we generate the earnings forecast score of WHWK?
To calculate the earnings forecast score of WHWK, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on WHWK’s future.
How do we generate the price momentum score of WHWK?
When generating the price momentum score for WHWK, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of WHWK’s prices. A higher score indicates a more stable short-term price trend for WHWK.
How do we generate the institutional confidence score of WHWK?
To generate the institutional confidence score of WHWK, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about WHWK’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of WHWK.
How do we generate the risk management score of WHWK?
To assess the risk management score of WHWK, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of WHWK’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of WHWK.
